A three-point scoring system that requires nothing more than a blood count, a brief assessment of a patient’s physical ...

Stereotactic body radiation therapy significantly improved quality of life outcomes, including urinary incontinence and ...

A phase III trial ancillary analysis found the Decipher Prostate Test predicts which intermediate-risk prostate cancer ...

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...

There is a moment in a prostate cancer consultation when I sometimes wish I could slow time down. The patient has already been through the blood test, the scan and ...

The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510 (k) supported by the HYDROSPACE trial.

The pre-formed and radiopaque flex hydrogel spacer is now FDA approved and will begin limited distribution in the US. The US Food and Drug Administration (FDA) has granted 510 (k) clearance for ...

“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026. SOU ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...